Pre-medication regimen showed an infusion-related reaction rate of 22.5 percent with intravenous RYBREVANT ®, a three-fold reduction from 67.4 percent historically seen with standard IRR management ...

The development of gene editing tools, which enable the specific targeting and correction of mutations, hold the promise of allowing us to correct those mutations that cause genetic diseases. However, ...

How Do Opdivo and Opdivo Qvantig Work for Lung Cancer? Some cancer cells have what are called checkpoint proteins on their cell surface. The immune cells in our bodies also have proteins on their ...

Tuesday, Johnson & Johnson (NYSE:JNJ) announced results from the open-label Phase 2 SKIPPirr study, which evaluated additional prophylactic strategies to reduce the incidence of infusion-related ...

Some studies have suggested that morning is the optimal time for immunotherapy, but a new analysis of patients with lung ...

Please provide your email address to receive an email when new articles are posted on . The ECMO system can get in the way of cell therapy delivery. Consecutive Intrabronchial Administration may be an ...

Researchers at the Institute of Industrial Science, The University of Tokyo have developed a system that allows human lung ...

--Johnson& Johnson today announced results from the open-label Phase 2 SKIPPirr study, which evaluated additional prophylactic strategies to reduce the incidence of infusion-related reactions with ...